Immuneering

Immuneering

Biotechnology
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

$238.3M

Market Cap • 11/6/2026

2008

(18 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,6

EPS

—

Market Cap

Market Cap

238,3M

EV

96,5M

EV/Revenue

0

EV/EBITDA

-1,3

EV/EBIT

-1,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-335,2M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

66,3%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

2,1%

% Goodwill

3,7%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

20,9%

CAGR Net Income 5Y

18,4%

CAGR EPS 5Y

-25,6%

CAGR OCF 5Y

17,9%

Leverage

N.D./EBITDA

1,9

Debt/Equity

0%

Current Ratio

14

Quick Ratio

13,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium